Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Uterine Cervical Neoplasms 1Rectal Neoplasms 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Malignant mesenchymal tumor 1Colorectal Neoplasms 1Carcinoma 1Anus Neoplasms 1

Interventions

Vincristine 3Radiotherapy 3Ifosfamide 3Etoposide 3Doxorubicin 3Dactinomycin 3Cyclophosphamide 3Carboplatin 3Epirubicin 2romidepsin 1cixutumumab 1Vinorelbine 1Topotecan 1Temozolomide 1Peripheral Blood Stem Cell Transplantation 1Neoadjuvant Therapy 1NHS-IL12 immunocytokine 1Molecular Diagnostic Techniques 1Microarray Analysis 1HhAntag691 1Filgrastim 1Chemotherapy, Adjuvant 1Brachytherapy 12,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Malignant mesenchymal tumor × NHS-IL12 immunocytokine × Clear all
NCT01417546 2021-10-18

NHS-IL12 for Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
72 enrolled

Malignant mesenchymal tumor, Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡